Christine Martin

Christine Martin has held a variety of roles in the life sciences industry since 2011. Christine began their career at Cambridge Enterprise as Head of Seed Funds, before taking on the roles of Interim Head of Seed Funds, Acting Head of Seed Funds, Deputy Head of Seed Funds, Head of Life Science Investment, Acting Head of Seed Funds, Investment Manager (Life Sciences), Manager of Drug Discovery, and Senior Technology Associate. In 2020, they began working as a Director for SDS Therapeutics, Spirea, Qkine, PolyProx Therapeutics Ltd, and PharmEnable. Christine has also held the role of Board Observer for Bilitech Limited, Carrick Therapeutics, Concr, and APCINTEX LIMITED since 2018, 2017, 2021, and 2017 respectively.

Christine Martin attended the University of Oxford from 1988 to 1995, where they obtained their MA and DPhil in Chemistry.